Drug Trial Radar · NCT02464670
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jun 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
May 2015
Primary completion
May 24, 2018
Study completion May 24, 2018
Sponsor
- Lead sponsor
- Inovio PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- GeneOne Life Science, Inc.; Defense Advanced Research Projects Agency
- First posted
- Jun 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.
Conditions
- Ebola Vaccine
Interventions
INO-4201Biological
INO-4201 delivered IM followed by Electroporation
INO-4202Biological
INO-4202 delivered IM followed by Electroporation
INO-4201Biological
INO-4201 delivered ID followed by Electroporation
INO-4212Biological
INO-4212 delivered IM followed by Electroporation
INO-4212 + INO-9012Biological
INO-4212 + INO-9012 delivered IM followed by Electroporation
INO-4201 + INO-9012Biological
INO-4201 + INO-9012 delivered ID followed by Electroporation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Assessment (Composite of multiple measures: adverse events, pain (VAS), lab abnormalities, changes in vital signs)Time frame: Screening through up to 60 weeks following the first dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
QPS MRA
Miami, Florida
The Center for Pharmaceutical Research
Kansas City, Missouri
University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.